chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was considered medically important (OMIC). Information regarding Prevenar (pneumococcal 7-valent conjugate vaccine (diphtheria crm197 protein) injection) was received from a consumer regarding a 2 month old female patient who experienced visible seizures, lasting 1-15 seconds, several times every day since 3/14/2006. The patient received the first dose on 3/14/2006. The patient also received a dose of Hib Titer vaccine (haemophilus B conjugate vaccine (diphtheria crm 197 protein conjugate injection), manufacture unknown, a dose of Poliomyelitis vaccine inactivated manufacturer unknown, and a dose of hepatitis B vaccine manufacturer unknown on 3/14/2006. The patients concurrent illness included convulsion (non visible, detected at birth) wit a past history of birth trauma. Indication for Prevnar was immunisation. Product was administered on 3/14/2006. Dose regimen was 1 dose 1 time per day intramuscular. Concomitant therapy included phenobarbital. On 3/14/2006, two hours after receiving her vaccinations, the patient had a visible seizure at home (convulsion) (condition aggravated). They now occur several times every day, lasting 1-15 seconds. The seizures were described as arm twitching, sometimes making the patient or leg quiver. The mother reported that she can stop the leg movement, but no the arm movement. It was noted that the patient had experienced some trauma during her birth on 1/11/2006. An EEG performed detected seizures that were not visible, the patient was then placed on Phenobarbital. Since the seizure activity has become visible, the patient is also receiving Tegretol (Carbamazepine), 7.5 ml daily. As of 6/6/2006, the patient has not recovered.
Severe dizziness, headache, muscle pain, fatigue, sore arm, electrical feeling zaps in legs.
BOTH KNEES SWOLLEN AND UNCOMFORTABLE; KNEES WARM TO TOUCH; HEADACHE; ICKY; WEAK; TIRED; LOW GRADE FEVER; PAIN; This spontaneous report received from a patient concerned a 59 year old female. The patient's height, and weight were not reported. The patient's past medical history included ankle replacement, and knee replacement, and concurrent conditions included penicillin allergy, nonsmoker, and non alcohol user, and other pre-existing medical conditions included the patient had no drug abuse or illicit drug usage. The patient experienced drug allergy when treated with chloramphenicol. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 041A21A, expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced pain. Treatment medications included: paracetamol. On 10-APR-2021, the subject experienced icky. On 10-APR-2021, the subject experienced headache. On 10-APR-2021, the subject experienced weak. On 10-APR-2021, the subject experienced tired. On 10-APR-2021, the subject experienced low grade fever. Laboratory data included: Body temperature (NR: not provided) over 100 F. On 13-APR-2021, Laboratory data included: COVID-19 virus test (NR: not provided) Negative. On 20-APR-2021, the subject experienced both knees swollen and uncomfortable. On 20-APR-2021, the subject experienced knees warm to touch. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from icky, headache, weak, and tired on 18-APR-2021, and low grade fever on 11-APR-2021, had not recovered from both knees swollen and uncomfortable, and the outcome of knees warm to touch and pain was not reported. This report was non-serious.
The patient received the third dose on day 14 instead of day 21; Case reference number US-BN-2021-002550 is a spontaneous case report initially received on 20-Dec-2021 from a pharmacist via Agency (reference number: USBAV21-0641) and concerns an adult female patient.  The patient's medical history and concomitant medication details were not provided.  On an unspecified date, the patient was vaccinated with the first two doses of RabAvert (inactivated rabies virus vaccine; batch number: unknown), at an unknown dose, intramuscularly, for pre-exposure immunization.   On an unspecified date, 14 days after the first dose, the patient was vaccinated with the third dose of RabAvert (inactivated rabies virus vaccine; batch number: unknown), at an unknown dose, intramuscularly, for pre-exposure immunization (explicitly coded as 'Inappropriate schedule of vaccine administered').  At the time of initial report, it was unknown whether the patient experienced any adverse event due to RabAvert vaccine.  Additional information received on 21-Dec-2021 via Agency included reporter, patient and vaccine details.  Additional information received on 21-Dec-2021 included local RA case ID.  No further information was provided.; Reporter's Comments: The 25-year-old female patient was vaccinated with the first two doses of RabAvert for pre-exposure immunization. Reportedly, on the day 14, the patient was vaccinated with the third dose of RabAvert, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. The inappropriate schedule of product administration is considered as listed per convention. The patient's medical history and concomitant medication details were not provided. The inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human action. This case is considered as non-serious.; Sender's Comments: The 25-year-old female patient was vaccinated with the first two doses of RabAvert for pre-exposure immunization. Reportedly, on the day 14, the patient was vaccinated with the third dose of RabAvert, which is considered as inappropriate schedule of product administration. No associated adverse events have been reported with the reported medication error. The inappropriate schedule of product administration is considered as listed per convention. The patient's medical history and concomitant medication details were not provided. The inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human action. This case is considered as non-serious.
pt brought to ED with fevers; states tested positive day before for COVID: hypoxic; placed on NRB mask; hypotensive; hx of sepsis and sacral decubitus wound; PEG feedings; given steroids, ABX, remdesivir; pt's condition worsened; he was made DNR, and he passed away in the hospital
12 year old here for second dose of Pfizer, was inadvertently given booster 0.25 mL of Moderna instead of Pfizer.
2nd dose give too soon. Pt's first dose was 8/11/21. 2nd dose was given on 9/2/21.
Patient came in to pharmacy on November 30th around 3pm to state her arm was swollen and hard feeling where the injection was given. She has use of her arm and no issues only painful if pressed on it and skin discolortion. She is going to MD appt on Friday Dec 7th and has not seen a doctor yet due to her traveling for vacation.
itching all over; This is a spontaneous report from a contactable Nurse (patient). An 82-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left on 18Feb2021 (Batch/Lot Number: EL9267; Expiration Date: May2021) (at the age of 82 years) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history was not reported. Concomitant medication included an unspecified medicine. The patient experienced itching all over (reported as non-serious) on 18Feb2021 with outcome of not recovered. Patient took the COVID shot, the first dose, and she has been itching ever since. Patient thought it was something else at first, but then went off that medicine for three days and the itching was still just as bad as it was when she was on that medicine. The outcome of event was not recovered.  No follow-up attempts are possible. No further information is expected.
Right arm swelling; 2 lumps in the armpit region (one in the center and the other near right breast); 2 lumps in the armpit region (one in the center and the other near right breast); Pain in the armpit; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Right arm swelling), MASS (2 lumps in the armpit region (one in the center and the other near right breast)), BREAST MASS (2 lumps in the armpit region (one in the center and the other near right breast)) and AXILLARY PAIN (Pain in the armpit) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Right arm swelling), MASS (2 lumps in the armpit region (one in the center and the other near right breast)), BREAST MASS (2 lumps in the armpit region (one in the center and the other near right breast)) and AXILLARY PAIN (Pain in the armpit). At the time of the report, PERIPHERAL SWELLING (Right arm swelling), MASS (2 lumps in the armpit region (one in the center and the other near right breast)), BREAST MASS (2 lumps in the armpit region (one in the center and the other near right breast)) and AXILLARY PAIN (Pain in the armpit) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Development of diarrhea in <24 hours which progressed to bloody diarrhea. Abdo XR (-), abdo U/S (-).
Patient received J&J COVID Vaccine 4/12/21 around 12:05 pm. Patient waited in waiting area and complained to her husband about feeling dizzy and might faint. Pharmacists went to aid the patient and lay her down gently, monitored her blood pressure which was high at the time, once patient sat up her BP decreased, it fluctuated the whole time, EMT was called and once they arrived and monitored her, they said the cause of her fainting was due to her blood pressure. Patient was alert and responsive the whole time. Patient was unsure if she took her BP medicine this morning.
Sl. swelling in R hand 9:48 a.m.; sl. itching L eye at 9:53 a.m.; rash under L eye-red and sl. raised.  No itching at 10:14 a.m.  Benadryl 50 mg IM administered L deltoid at 10:15 a.m.  Monitored and released back to class with no swelling in hand; less redness of rash under eye.  Follow up with mother today who states patient is doing fine. No problems.  Did not have to take child to doctor or ER.
Injection site red; Puffy rash around the injection site bigger than a quater; Swollen around the injection site; Itchy around the injection site; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE ERYTHEMA (Injection site red), VACCINATION SITE RASH (Puffy rash around the injection site bigger than a quater), VACCINATION SITE SWELLING (Swollen around the injection site) and VACCINATION SITE PRURITUS (Itchy around the injection site) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included VITAMINS NOS for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Injection site red), VACCINATION SITE RASH (Puffy rash around the injection site bigger than a quater), VACCINATION SITE SWELLING (Swollen around the injection site) and VACCINATION SITE PRURITUS (Itchy around the injection site). The patient was treated with HYDROCORTISONE (topical) in March 2021 for Vaccination site erythema, Vaccination site rash, Vaccination site swelling and Vaccination site pruritus, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (topical) in March 2021 for Vaccination site pruritus, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE ERYTHEMA (Injection site red), VACCINATION SITE RASH (Puffy rash around the injection site bigger than a quater), VACCINATION SITE SWELLING (Swollen around the injection site) and VACCINATION SITE PRURITUS (Itchy around the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Additional treatment information included breast milk, on the injection site to treat adverse event.
Rash, low grade fever developed 7/22/07. Hot/cold chills. (Pruritic mildly). Tx-sx managed with Tylenol and Benadryl. Mild illness. Prognosis is good for full recovery.
Swelling of injection site. Redness and rash on chest  and arm area for a couple of days. Went away on its own.
Pressure in her chest; Headache; Injection site soreness; This spontaneous case was reported by a consumer and describes the occurrence of   in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   No treatment information was reported.    Reporter did not allow further contact
patient reported to pharmacy on 12/16/21 that dr wanted her to report information the pharmacy. Pt received vaccine on 03/11/21 and reported to Dr feeling fatigue in May 2021. Patient reported to dr was having trouble breathing August 2021. Patient reported that she was diagnosed with pulmonary embolism on 10/27/21
Patient's father called and stated his son reported parathesia in eyes 30 minutes after test but not in his arm. Patient was instructed to take benadryl and pepcid as a precaution and contact their primary care physician if symptoms persist
12:17 PM  Patient started feeling lightheaded and felt heart rate up.  Feeling pressure behind ears.  Vitals were taken:  BP 152/102, Pulse 115, O2 98%, Respiration 18, Temp 97.9 12:22PM Patient started feeling better, stated episode had passed.  High blood pressure runs in his family.  Offered to retake vitals, patient refused.  Advised to monitor blood pressure and see his primary care doctor.  Monitored for additional 15 minutes, patient stated he  felt better.  Patient was cleared.
Adverse event was body aches and intense headaches for two days after the adverse symptoms started. This is only after the second vaccine. There was no reaction other than arm soreness after the first vaccine. At the time of the second vaccine, I was 13 weeks pregnant due to deliver on October 31, 2021.
nausea Narrative:  43 yo female with PMH of GERD, bipolar, panic attack, insomnia, OSA, obesity, knee joint pain, HTN, hx of suicide attempt, hypothyroidism, carpal tunnel syndrome, vitamin D deficiency reported having nausea during the observation post COVID19 vaccine (Pfizer). Pt was taken to a private room to rest. BP 160/107, HR 82, RR 26, temp 98.4 and 100% O2. After laying down for five minutes, nausea down to 1/10. BP retake 150/97, HR 80, O2 99%. Patient had LTK surgery on 2/3/21; Knee pain today 5/10. Patient also states she has history of anxiety and panic attacks. Patient rated nausea 0/10 upon release from covid-19 vaccine recovery area at 12:45. BP 141/94, HR 87. Patient stated she felt fine and comfortable leaving. Prior to getting vaccinated, she patient denied any prior severe reaction to this vaccine or its components or a severe allergic reaction such as anaphylaxis to any vaccine or to any injectable therapy. Of note, patient has a prior positive with OVID19 ON 12/30/2020.
shortly after received MENVEO and BEXSERO vaccines (Given simultaneously in different arms)-2/15/17 at 4pm. Developed  flushing, nausea, body aches, sweats. Continued until today's apt (2/16/17 at 0900).
Case number PHEH2015US001090 is an initial combined spontaneous report received from a health care professional on 12 Jan 2015 with a follow up information received from a physician on 13 Jan 2015 This report refers to an 11 years old male patient. His medical history and concomitant medications were not reported. He was vaccinated with MenCYW-135 liquid component of MENVEO (batch number: X140711) intramuscularly on 12 Jan 2015 in error without reconstituting with Men A lyophilized powder conjugate. The physician reported that the patient either received one vial of the MenCYW-135 liquid component or two vials of MenCYW-135 liquid component on 12 Jan 2015. No adverse event was reported following the maladministration.
autoimmune disease consistent with those symptoms; Initial information was received on 24-Nov-2021 regarding an unsolicited valid serious social media case from a consumer/non-healthcare professional.  This case involves a patient (unknown demographics) who had autoimmune disease consistent with those symptoms (autoimmune disorder)  after receiving INFLUENZA VACCINE.  It was unknown if the patient had any medical history, concomitant disease or risk factor.  The patient's past medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On an unknown date in 2003, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date were not reported) via an unknown route at an unknown administration site for prophylactic vaccination. Patient almost immediately started having symptoms.  On an unknown date in 2004,  the patient was diagnosed with a serious autoimmune disease consistent with those symptoms (autoimmune disorder) (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant. Patient still has that condition. Patient would rather have had the sniffles, and if memory serves,  still got sick anyways.  Patient think there's something sinister going on with these vaccines, and the fraud, and lies they are fed about the corona virus disease (COVID) vaccine only serves to reinforce the idea that patient may be right.  It was unknown if the patient experienced any additional symptoms/events.  There were no lab data/results available.  It was not reported if the patient received any corrective treatment for the events.  At time of reporting, the outcome was Unknown for both the events.  Information on batch number is requested.; Sender's Comments: This case concerns a patient (unknown demographics) who had autoimmune disorder after vaccination with  INFLUENZA VACCINE (unknown manufacturer).The time to onset is unknown. However, there is no further information regarding patient's medical condition at the time of vaccination, concomitant medication(s) and laboratory tests ruling out other alternate etiologies were not reported. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
Developed Shingles outbreak.  No reason for it.  Had them before - maybe 25 years ago.
Pt states bad migraine and felt really achy all over body. Chills and then fever. Feel extremely tired.
SOB, fever, headache, pressure on chest when breathing, cough, rash, itchy. Pt stated they all started 24 hrs after she received the immunization. Lasting couple of weeks. Rash continued to today moved from head to abdomen and down to groin.
First shingirx in 2019, second on 2022; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 74-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2019).   On 2nd February 2022, the patient received the 2nd dose of Shingrix. On 2nd February 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were reported as follows: The patient self-reported this case. The patient stated he/she received 2nd dose of Shingrix which was longer than the six months recommended schedule, which led to lengthening of vaccination schedule. The patient wanted to know if he/she was protected. The patient stated that a pharmacist said he/she was protected and wanted to verify the same. The patient was advised to refer his/her health care provider as his/her primary resource for patient care.  The patient was informed, the Food and Drug Administration (FDA) approved dosing schedule for Shingrix was the first dose at month 0, followed by a second dose 2-6 months after the first dose. GlaxoSmithKline had not done its own studies on the time frame greater than 6 months, but the Centers for Disease Control (CDC) had provided guidance that if it had been more than 6 months since a patient received the first dose, they should get the second dose as soon as possible; patients do not need to restart the vaccine series. They had no indications if it had been longer than 6 months between getting the two Shingrix vaccines that the coverage was any less. The patient was provided with the link for the package insert. The patient was further informed that Shingrix was shown to be over 90 percent effective at preventing shingles for people 50 years of age and older in clinical trials after receiving both doses. The patient appreciated the link and stated that was all he/she needed.
Prior to 3 doses of GARDASIL I had all normal pap tests between the years 2004 to 12-1-20066.  After 3 doses of GARDASIL I had 2 abnormal pap tests.  I also had a yeast infection on my right armpit, and on/ about 11-2008, I was seen by my OBGYN for a swollen gland in my groin area.
Headache, Arthralgia, Fever,  FATIGUE, CHILLS, LOCAL LYMPHNODE TENDERNESS/SWELLING ON SITE SIDE, SITE PAIN/SWELLING Narrative:
Rash on upper chest, neck, and face. Tried Benadryl with gradual improvement.
mom called 3PM 11SEp96 to report that pt had not woke up since 10PM 10SEP & temp was 104 even w/APAP;mom referred to PMD  & ER ASAP;states has been giving APAP;none since 6AM to ER report pending;
Headache, Fever, Diarrhea, fatigue, pain upper back and neck Narrative:
Received vaccine on 11/17/00 at 10:00 and at 14:00 was unable to abduct right arm. At 18:00, had nausea, pain at site and fever of 101F. Nausea and fever duration of 12 hours. Inability to abduct arm for 1 week. Pain right shoulder for more than 3 weeks. Orthopedic MD dx'd muscular allergy to vaccine; this individual only.
nausea; bronchitis like cough that is bringing up flim; This is a spontaneous report from a contactable Consumer (patient). A 40-year-old female received bnt162b2 (Pfizer-biontech covid-19 vaccine, Solution for injection, Batch/lot number: unknown) via an unspecified route of administration on 12Aug2021 as DOSE 1, SINGLE for covid-19 immunization. The patient's medical history included Cold (she had a cold she had just gotten over before receiving the vaccine.) on an unknown date and not ongoing. The concomitant medications were not reported. On Aug2021 patient had experienced nausea and bronchitis like cough that is bringing up flim and also reported that, are these normal side effects following the vaccine. The clinical outcome of the events were unknown .  Information on the lot/batch number has been requested